Compare Emerson Electric Co. (EMR) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Emerson Electric Co. vs Twist Bioscience Corp — how do they compare? Emerson Electric Co. trades at $164.49 (market cap $91.69B), while Twist Bioscience Corp trades at $124.35 (market cap $7.72B). The key difference: Emerson Electric Co. is far larger — about 11.9× Twist Bioscience Corp's market cap, and Emerson Electric Co. pays a 1.35% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| EMR | TWST | |
|---|---|---|
Market Cap | $91.69B | $7.72B |
Sector | Industrials | Health |
52-Week High | $164.38 | $124.88 |
52-Week Low | $123.30 | $24.16 |
Enterprise Value | $102.77B | $7.65B |
Dividend Yield | 1.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Emerson Electric (EMR) trades at $164.56, up 3.7% on the day, reflecting strong momentum after three consecutive quarterly earnings beats. The stock exhibits a bullish technical setup, with key resistance at $168, while fundamentals show solid revenue growth and a 13.83% net income margin. Recent news highlights Q3 2026 results exceeding expectations, driven by 7% organic growth and strategic acquisitions like Glue Inc. to bolster AI capabilities in test and measurement.
Outlook remains positive with raised 2026 guidance, though valuation multiples like a P/E of 35.97 suggest premium pricing. Risks include execution challenges in integrating acquisitions and macroeconomic pressures on industrial demand. Analyst consensus favors Buy ratings with a $171.33 price target, indicating modest upside potential from current levels.
TWST is trading at $124.88, up 7.96% in the last 24 hours, near its pivot point of $121 with resistance at $129. The stock shows strong technical momentum with bullish moving averages, though RSI levels indicate overbought conditions. Revenue growth is robust, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, but the company remains unprofitable with a net income margin of -31.66% and negative cash flow from operations. Recent news highlights an upsized $300 million public offering and expansion in AI-driven drug discovery.
The outlook for TWST is mixed; bullish analyst sentiment and AI growth potential are offset by persistent losses and high valuation multiples. Investment opportunity lies in sustained revenue expansion and path to profitability, but risks include cash burn, competitive pressures, and execution challenges in scaling operations. The stock's current price exceeds the consensus target of $106.14, suggesting limited near-term upside based on fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Emerson Electric Co.
Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.
Read more on EMR →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
